October 2009

Teaser

November December 2009

Teaser

Winter 2010

Teaser

  • Abbott Buys Facet Biotech for $722 Million
    From Facet Biotech
    Abbott and Facet Biotech Corporation announced today a definitive agreement for Abbott to acquire Facet, enhancing Abbott's early- and mid-stage pharmaceutical pipeline. ... (Read more)
  • Scientists Shed New Light On How Retina's Hardware Is U...
    From Medical News Today
    Biologists at New York University and the University of Würzburg have identified, in greater detail, how the retina's cellular hardware is used in color preference. The ... (Read more)
  • ISTA says FDA to review eye drug by Oct. 16
    From Associated Press
    ISTA Pharmaceuticals Inc. said Monday the Food and Drug Administration will make a regulatory decision on the once-daily eye inflammation treatment XiDay by Oct. 16. The ... (Read more)
  • Cataract risk increases with anti-depressants
    From The Times of India
    Researchers at the University of British Columbia, Vancouver Coastal Health Research Institute and McGill University have found that some anti-depressant drugs are associ... (Read more)
  • High eye pressure: monitor or treat?
    From Washington University in St. Louis
    Most people at risk for developing glaucoma due to high eye pressure do not need treatment, according to a large, multi-center study. The Ocular Hypertension Treatment St... (Read more)

Subscribe to EyewireToday.com

e-dition

Mission Statement

Glaucoma Today is mailed quarterly to 12,706 glaucoma specialists and general ophthalmologists who treat patients with glaucoma. Since 2008, this database has grown by approximately 20%. Glaucoma Today delivers important information on recent research, surgical techniques, clinical strategies, therapeutics, and technology. Additionally, the publication profiles leaders in the field of glaucoma, and contributing authors present challenging cases as a source of education for readers. Glaucoma Today delivers balanced coverage of the topics that matter most.

Meetings

  • Check back soon for upcoming events.